Key Takeaways
- • Atavistik Bio secured $120 million in Series B funding to advance its pipeline of selective allosteric small molecule therapeutics targeting hereditary hemorrhagic telangiectasia (HHT) and myeloproliferative neoplasms (MPNs), demonstrating sustained investor confidence in precision medicine approaches to rare blood disorders.
- • Global biotech venture capital funding surged approximately 70.9% in 2025, with deal value climbing from $1.8 billion in Q2 to $3.1 billion by October, indicating robust market conditions for biotech financing despite macroeconomic headwinds.
- • Syneron Bio successfully secured new funding as part of the broader capital deployment wave tracked in the Fierce Biotech Fundraising Tracker, signaling continued investor appetite for established biopharma companies.
- • Cambridge-based Atavistik's fundraising underscores the market's focus on early- to mid-stage biotech with differentiated mechanisms of action (allosteric therapeutics) and applications in underserved therapeutic areas.
Summary
Atavistik Bio, a Cambridge, Massachusetts-based biotechnology company, closed a $120 million Series B financing round announced on December 18, 2025. The company focuses on discovering and developing precision allosteric therapeutics—small molecules that modulate protein function through non-orthosteric binding sites—for treating hereditary hemorrhagic telangiectasia (HHT) and myeloproliferative neoplasms (MPNs), rare but serious blood disorders with limited therapeutic options.
The fundraising capital will support advancement of Atavistik's pipeline of selective allosteric small molecule therapeutics through clinical and preclinical stages. The company's focus on allosteric mechanisms represents a differentiated approach within the broader precision medicine landscape, targeting disease areas where conventional therapeutic strategies have faced limitations.
Atavistik's Series B raise occurs within a period of significant momentum in biotech venture capital. According to the Fierce Biotech Fundraising Tracker, global biotech VC deal value surged approximately 70.9% between Q2 and October 2025, climbing from $1.8 billion to $3.1 billion, reflecting strong investor appetite for early- and mid-stage biopharma innovation despite broader economic uncertainty.
Alongside Atavistik's raise, Syneron Bio also secured new funding, as documented in the December 19, 2025 Fierce Biotech Fundraising Tracker update. The tracker serves as a comprehensive record of venture capital deployment into the biopharma sector throughout 2025, capturing the scale and scope of institutional investor interest in biotechnology innovation during the year.
The fundraising capital will support advancement of Atavistik's pipeline of selective allosteric small molecule therapeutics through clinical and preclinical stages. The company's focus on allosteric mechanisms represents a differentiated approach within the broader precision medicine landscape, targeting disease areas where conventional therapeutic strategies have faced limitations.
Atavistik's Series B raise occurs within a period of significant momentum in biotech venture capital. According to the Fierce Biotech Fundraising Tracker, global biotech VC deal value surged approximately 70.9% between Q2 and October 2025, climbing from $1.8 billion to $3.1 billion, reflecting strong investor appetite for early- and mid-stage biopharma innovation despite broader economic uncertainty.
Alongside Atavistik's raise, Syneron Bio also secured new funding, as documented in the December 19, 2025 Fierce Biotech Fundraising Tracker update. The tracker serves as a comprehensive record of venture capital deployment into the biopharma sector throughout 2025, capturing the scale and scope of institutional investor interest in biotechnology innovation during the year.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.